




PHARMACEUTICAL 2022

Rezolute Inc.
Rank 279 of 466





PHARMACEUTICAL 2022

Rezolute Inc.
Rank 279 of 466

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Rezolute Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 81%, being 3.2% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	41,993
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,968
Liabilities, Non-Current	187
Other Assets	587
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	14,355
Other Net Income	1,992
Other Revenues	0
Property and Equipment	29
Research and Development	14,987
Selling, General and Administrative Expense	7,907

Output Variable	Value in 1000 USD
Assets	42,609
Liabilities	16,510
Expenses	22,894
Revenues	0
Stockholders Equity	26,099
Net Income	-20,902
Comprehensive Net Income	-20,902
Economic Capital Ratio	81%